Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Resverlogix Completes Dosing in ASSURE Clinical Trial

Published: Friday, September 06, 2013
Last Updated: Friday, September 06, 2013
Bookmark and Share
IVUS data will evaluate plaque regression in patients with high-risk cardiovascular disease.

Resverlogix Corp. has announced that it has completed dosing in ASSURE, a Phase 2b clinical trial evaluating RVX-208, Resverlogix's first-in-class orally active BET-protein inhibitor, using intra-vascular ultrasound (IVUS) in high-risk cardiovascular patients with low HDL and ApoA-I (n=324).

These target patients have significant residual risk in major adverse coronary events (MACE) such as heart attack, unstable angina, stroke, revascularization and death, despite standard of care therapy such as statins.

The main underlying cause of the residual risk in these patients is atherosclerosis. ASSURE is designed to evaluate the ability of RVX-208 to regress atherosclerotic disease.

"Atherosclerosis regression represents a new paradigm in the treatment of high-risk cardiovascular disease patients," said Donald McCaffrey, president and chief executive officer of Resverlogix. "The completion of the ASSURE trial is a major development milestone for the company. RVX-208 is the first small molecule BET inhibitor that raises the production of ApoA-I to be tested in a landmark IVUS trial."

ASSURE is a 26-week, multi-center, double-blind, randomized, parallel group, placebo-controlled trial led by the Cleveland Clinic.

To assess atherosclerosis regression in ASSURE, all subjects were examined using IVUS. The primary endpoint in ASSURE is to detect a change in percent atheroma volume as determined by IVUS at baseline vs. 26 weeks of treatment.

The use of IVUS technology will provide details regarding plaque composition and stability, which is important because both are elements leading to acute coronary syndrome.

Secondary endpoints for ASSURE include safety and tolerability of RVX-208, effects of the compound on plasma ApoA-I, HDL-C, HDL-subclasses and non-HDL lipid parameters such as the CRP inflammation marker. Top line data is expected mid-2013.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority
Company expects to launch the upcoming BETonMACE Phase 3 clinical trial.
Tuesday, June 23, 2015
Resverlogix Presents New Data at 52nd Annual ERA-EDTA Congress
RVX-208, the first selective bromodomain extra-terminal (BET) protein inhibitor, significantly reduces alkaline phosphatase (ALP) levels in patients with high vascular risk.
Thursday, June 04, 2015
Resverlogix and Hepalink Announce a Combination Licensing and Equity Arrangement
The deal structure involves CAD$50 million in equity investments, and future China sales milestones and licensing royalties that could represent in excess of US$400 million.
Thursday, May 07, 2015
Resverlogix Presents at Biotech Showcase During JP Morgan Week
Donald McCaffrey share developments of the Company's proposed new phase 3 clinical trial BETONMACE.
Thursday, January 15, 2015
Resverlogix Appoints Senior Vice President of Clinical Development
Appointment of Michael T. Sweeney, M.D., as senior vice president.
Tuesday, November 04, 2014
RVX-208 Reduces MACE Significantly in Patients with Diabetes Mellitus
In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose metabolism.
Thursday, July 24, 2014
Resverlogix Secures an Additional $30 Million from Citibank Loan
Special meeting of shareholders called to approve.
Saturday, July 05, 2014
Resverlogix Granted European Patent
European Patent office grants RVX-208 patent until 2027.
Tuesday, March 18, 2014
Resverlogix Announces Two New Findings from the Phase 2b ASSURE Trial
RVX-208 lowers inflammation and MACE events while regressing atheroma in high risk CVD patients.
Monday, November 11, 2013
Resverlogix Reports Top-Line Results from ASSURE Clinical Trial
Company’s Phase 2b clinical trial evaluating RVX-208 did not meet its primary endpoint.
Friday, June 28, 2013
Resverlogix Establishes Clinical & Scientific Advisory Board
Dr. Bengt Winblad appointed Chairman of the clinical & scientific advisory board.
Wednesday, December 26, 2012
Resverlogix Initiates Phase 2 Clinical Trial of RVX-208
Data expected in the first half of 2014.
Friday, October 19, 2012
Resverlogix Completes Enrollment in ASSURE Trial
IVUS data will evaluate plaque regression in patients with coronary artery disease.
Monday, October 01, 2012
Resverlogix' RVX-208 is the First BET Bromodomain Inhibitor in Clinical Trials
This novel epigenetic mechanism defines an entirely new class of therapeutic.
Tuesday, July 24, 2012
Resverlogix Completes Dosing of RVX-208 in SUSTAIN
Company expects to report top line data for SUSTAIN in Q3 2012.
Monday, July 02, 2012
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!